Analyst Research

Report Title Price
Provider : Wright Reports
Provider : New Constructs, LLC
Provider : Reuters Investment Profile
Provider : Ford Investor Services, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CEL-SCI Corp receives approval to expand Immunotherapy Phase III Head and Neck Cancer Trial into United Kingdom

Monday, 2 Jun 2014 09:30am EDT 

CEL-SCI Corp:United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted regulatory approval to begin company's Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection) in United Kingdom (UK).Several hospitals and medical clinics in the UK are expected to participate in the Phase III trial for the treatment of head and neck cancer. 

Company Quote

-0.0017 -0.25%
6 Oct 2015